FDA Approves Feasibility Trial Of Disappearing Tissue Tricuspid Valve
This article was originally published in The Gray Sheet
Executive Summary
CorMatrix Cardiovascular’s CorMatrix ECM tricuspid heart valve is a flexible, unstented valve that works as a replacement valve while also providing the scaffold on which the patient’s own tissue can form a new valve.
You may also be interested in...
New Products In Brief
CorMatrix Cardiovascular’s ECM
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.